Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women

Cancer Medicine

Volumn 6, Issue 1, 2017, Pages 207-219

  Li, Xia ^a   Huang, Hailiang ^b,c   Guan, Yanfang ^d   Gong, Yuhua ^d   He, Cheng Yi ^a   Yi, Xin ^d   Qi, Ming ^e,f,g   Chen, Zhi Ying ^a  

^a SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d Geneplus Beijing ^*  (China)

^e BGI SHENZHEN   (China)

^f ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; immunotherapeutic target; neo epitope; phylogenetic tree

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; SCLEROPROTEIN; UBIQUITIN; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CARCINOGENESIS; CELL KILLING; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; FBXW7 GENE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATION RATE; PHYLOGENETIC TREE; PIK3CA GENE; PREDICTION; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UTERINE CERVIX CANCER; WHOLE EXOME SEQUENCING; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DNA SEQUENCE; EARLY CANCER DIAGNOSIS; EXOME; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; MUTATION; PAPILLOMAVIRUS INFECTION; PHYLOGENY; PROCEDURES; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CELL CYCLE PROTEINS; CHINA; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; EARLY DETECTION OF CANCER; EPITOPES; EXOME; F-BOX PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; MUTATION; PAPILLOMAVIRUS INFECTIONS; PHYLOGENY; SEQUENCE ANALYSIS, DNA; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS;

EID: 85007316275     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.953     Document Type: Article

References (58)

1. Brahmer, J. R., and D. M. Pardoll. 2013. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol. Res. 1:85–91.
2. Borghaei, H., L. Paz-Ares, L. Horn, D. R. Spigel, M. Steins, N. E. Ready, et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:1627–1639.
3. Chen, Z. Y., F. Ma, H. L. Huang, and C. Y. He. 2015. Synthetic immunity to break down the bottleneck of cancer immunotherapy. Sci. Bulletin. 60:977–985.
4. Gerlinger, M., A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883–892.
5. Nik-Zainal, S., P. Van Loo, D. C. Wedge, L. B. Alexandrov, C. D. Greenman, K. W. Lau, et al. 2012. The life history of 21 breast cancers. Cell 149:994–1007.
6. Waclaw, B., I. Bozic, M. E. Pittman, R. H. Hruban, B. Vogelstein, and M. A. Nowak. 2015. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 525:261–264.
7. Carreira, S., A. Romanel, J. Goodall, E. Grist, R. Ferraldeschi, S. Miranda, et al. 2014. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6:254ra125.
8. Eirew, P., A. Steif, J. Khattra, G. Ha, D. Yap, H. Farahani, et al. 2015. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518:422–426.
9. Gundem, G., P. Van Loo, B. Kremeyer, L. B. Alexandrov, J. M. Tubio, E. Papaemmanuil, et al. 2015. The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357.
10. Couzin-Frankel, J. 2013. Breakthrough of the year 2013. Cancer immunotherapy. Science 342:1432–1433.
11. Nik-Zainal, S., L. B. Alexandrov, D. C. Wedge, P. Van Loo, C. D. Greenman, K. Raine, et al. 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149:979–993.
12. GLOBOCAN 2012: Cervical Cancer Incidence, Mortality and Prevalence Worldwide in 2012 Avaliable at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx(accessed 12 June 2015).
13. Ojesina, A. I., L. Lichtenstein, S. S. Freeman, C. S. Pedamallu, I. Imaz-Rosshandler, T. J. Pugh, et al. 2014. Landscape of genomic alterations in cervical carcinomas. Nature 506:371–375.
14. Chung, T. K., P. Van Hummelen, P. K. Chan, T. H. Cheung, S. F. Yim, M. Y. Yu, et al. 2015. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int. J. Cancer 137:776–783.
15. FIGO Committee on Gynecologic Oncology. 2014. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int. J. Gynaecol. Obstet. 125:97–98.
16. Yi, X., J. Li, S. Yu, A. Zhang, J. Xu, J. Yi, et al. 2011. A new PCR-based mass spectrometry system for high-risk HPV, part I: methods. Am. J. Clin. Pathol. 136:913–919.
17. Li, H., and R. Durbin. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760.
18. McKenna, A., M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, et al. 2010. The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303.
19. Cibulskis, K., M. S. Lawrence, S. L. Carter, A. Sivachenko, D. Jaffe, C. Sougnez, et al. 2013. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31:213–219.
20. Genomes Project C; Auton, A.L. D. Brooks, L. D. Brooks, M. A. DePristo, and R. M. Durbin, et al. 2012. An integrated map of genetic variation from 1,092 human genomes. Nature 491:56–65.
21. Exome Variant Server. 2015. NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. Avaliable at: http://evs.gs.washington.edu/EVS/ (accessed 4 January 2015).
22. Exome Aggregation Consortium (ExAC). 2015. Cambridge, MA. Avaliable at: http://exac.broadinstitute.org. (accessed 4 January 2015)
23. McLaren, W., B. Pritchard, D. Rios, Y. Chen, P. Flicek, and F. Cunningham. 2010. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26:2069–2070.
24. Van Doorslaer, K., Q. Tan, S. Xirasagar, S. Bandaru, V. Gopalan, Y. Mohamoud, et al. 2013. The papillomavirus episteme: a central resource for papillomavirus sequence data and analysis. Nucleic Acids Res. 41:D571–D578.
25. Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102:15545–15550.
26. Jiao, W., S. Vembu, A. G. Deshwar, L. Stein, and Q. Morris. 2014. Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics 15:35.
27. Misra, N., E. Szczurek, and M. Vingron. 2014. Inferring the paths of somatic evolution in cancer. Bioinformatics 30:2456–2463.
28. Lundegaard, C., K. Lamberth, M. Harndahl, S. Buus, O. Lund, and M. Nielsen. 2008. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36:W509–W512.
29. Mootha, V. K., C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34:267–273.
30. Banerji, S., K. Cibulskis, C. Rangel-Escareno, K. K. Brown, S. L. Carter, A. M. Frederick, et al. 2012. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405–409.
31. Wright, A. A., B. E. Howitt, A. P. Myers, S. E. Dahlberg, E. Palescandolo, P. Van Hummelen, et al. 2013. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119:3776–3783.
32. Chung, T. K., P. Van Hummelen, P. K. Chan, T. H. Cheung, S. F. Yim, M. Y. Yu, et al. 2015. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int. J. Cancer 137:776–783.
33. Tran, E., S. Turcotte, A. Gros, P. F. Robbins, Y. C. Lu, M. E. Dudley, et al. 2014. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641–645.
34. Robbins, P. F., Y. C. Lu, M. El-Gamil, Y. F. Li, C. Gross, J. Gartner, et al. 2013. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19:747–752.
35. Trajanoski, Z., C. Maccalli, D. Mennonna, G. Casorati, G. Parmiani, and P. Dellabona. 2015. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol. Immunother. 64:99–104.
36. Castle, J. C., S. Kreiter, J. Diekmann, M. Lower, N. van de Roemer, J. de Graaf, et al. 2012. Exploiting the mutanome for tumor vaccination. Cancer Res. 72:1081–1091.
37. Guo, G., Y. Gui, S. Gao, A. Tang, X. Hu, Y. Huang, et al. 2012. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 44:17–19.
38. Welcker, M., and B. E. Clurman. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8:83–93.
39. Mao, J. H., I. J. Kim, D. Wu, J. Climent, H. C. Kang, R. DelRosario, et al. 2008. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321:1499–1502.
40. Tommasino, M., R. Accardi, S. Caldeira, W. Dong, I. Malanchi, A. Smet, et al. 2003. The role of TP53 in Cervical carcinogenesis. Hum. Mutat. 21:307–312.
41. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495–505.
42. Boyer, S. N., D. E. Wazer, and V. Band. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:4620–4624.
43. McCormack, S. J., S. E. Brazinski, J. L. Jr Moore, B. A. Werness, and D. J. Goldstein. 1997. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene 15:265–274.
44. Du, M., X. Fan, E. Hong, and J. J. Chen. 2002. Interaction of oncogenic papillomavirus E6 proteins with fibulin-1. Biochem. Biophys. Res. Commun. 296:962–969.
45. Chiarugi, P., and E. Giannoni. 2008. Anoikis: a necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 76:1352–1364.
46. Nowell, P. C. 1976. The clonal evolution of tumor cell populations. Science 194:23–28.
47. Hughes, A. E., V. Magrini, R. Demeter, C. A. Miller, R. Fulton, L. L. Fulton, et al. 2014. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet. 10:e1004462.
48. Aparicio, S., and C. Caldas. 2013. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368:842–851.
49. Vogelstein, B., N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Jr Diaz, and K. W. Kinzler. 2013. Cancer genome landscapes. Science 339:1546–1558.
50. Moody, C. A., and L. A. Laimins. 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10:550–560.
51. Samuels, Y., Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
52. Ciriello, G., M. L. Miller, B. A. Aksoy, Y. Senbabaoglu, N. Schultz, and C. Sander. 2013. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45:1127–1133.
53. Rusan, M., Y. Y. Li, and P. S. Hammerman. 2015. Genomic landscape of human papillomavirus-associated cancers. Clin. Cancer Res. 21:2009–2019.
54. Dumont, A. G., S. N. Dumont, and J. C. Trent. 2012. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J. Cancer 31:327–334.
55. Van Keymeulen, A., M. Y. Lee, M. Ousset, S. Brohee, S. Rorive, R. R. Giraddi, et al. 2015. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525:119–123.
56. Nguyen, L. V., D. Pellacani, S. Lefort, N. Kannan, T. Osako, M. Makarem, et al. 2015. Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. Nature 528:267–271.
57. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565–1570.
58. Coulie, P. G., B. J. Van den Eynde, P. van der Bruggen, and T. Boon. 2014. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14:135–146.